Literature DB >> 9219746

Age related cognitive decline: a clinical entity? A longitudinal study of cerebral blood flow and memory performance.

P Celsis1, A Agniel, D Cardebat, J F Démonet, P J Ousset, M Puel.   

Abstract

OBJECTIVES: To evaluate the changes in regional cerebral blood flow (rCBF) and memory performance in patients with age related cognitive decline (ARCD) who did and did not become demented during a follow up period.
METHODS: Twenty four patients with ARCD were recruited from an outpatient memory clinic, of whom 18 were followed up over a mean period of two years. Eighteen patients with mild to moderate probable Alzheimer's disease and 18 aged normal controls were followed up over a mean period of three years. Memory performance and rCBF were evaluated quantitatively at inclusion and during follow up, using single photon emission computed tomography with xenon-133 injection and three subtests of the Wechsler memory scale (logical memory, paired associated learning, and digit span).
RESULTS: Patients with ARCD showed decreased rCBF and memory performance at initial evaluation compared with controls. Five of them became demented during the follow up period, with further decline in memory and rCBF. At inclusion, the only feature that distinguished these five patients as a group from the remainder was a pronounced temporoparietal asymmetry. The 13 patients with ARCD who did not become demented still exhibited impaired memory and rCBF at follow up, but without any further decline and no increase in flow asymmetry.
CONCLUSIONS: Apart from patients in the preclinical phase of Alzheimer's disease, the ARCD category includes non-demented patients who have brain dysfunction that may represent a distinct clinical entity.

Entities:  

Mesh:

Year:  1997        PMID: 9219746      PMCID: PMC1074144          DOI: 10.1136/jnnp.62.6.601

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  24 in total

Review 1.  Age-associated memory impairment: sorting out the controversies.

Authors:  G J Larrabee; W J McEntee
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

Review 2.  Should aging-associated cognitive decline be included in DSM-IV?

Authors:  E D Caine
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1993       Impact factor: 2.198

3.  Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E epsilon 4 allele.

Authors:  H Soininen; K Partanen; A Pitkänen; M Hallikainen; T Hänninen; S Helisalmi; A Mannermaa; M Ryynänen; K Koivisto; P Riekkinen
Journal:  Neurology       Date:  1995-02       Impact factor: 9.910

4.  Volumetric MRI analysis of the amygdala and the hippocampus in subjects with age-associated memory impairment: correlation to visual and verbal memory.

Authors:  H S Soininen; K Partanen; A Pitkänen; P Vainio; T Hänninen; M Hallikainen; K Koivisto; P J Riekkinen
Journal:  Neurology       Date:  1994-09       Impact factor: 9.910

5.  Temporal lobe perfusion on single photon emission computed tomography predicts the rate of cognitive decline in Alzheimer's disease.

Authors:  N Wolfe; B R Reed; J L Eberling; W J Jagust
Journal:  Arch Neurol       Date:  1995-03

6.  Prevalence of age-associated memory impairment in a randomly selected population from eastern Finland.

Authors:  K Koivisto; K J Reinikainen; T Hänninen; M Vanhanen; E L Helkala; L Mykkänen; M Laakso; K Pyörälä; P J Riekkinen
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

7.  The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort.

Authors:  R T Linn; P A Wolf; D L Bachman; J E Knoefel; J L Cobb; A J Belanger; E F Kaplan; R B D'Agostino
Journal:  Arch Neurol       Date:  1995-05

8.  Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications.

Authors:  G S Smith; M J de Leon; A E George; A Kluger; N D Volkow; T McRae; J Golomb; S H Ferris; B Reisberg; J Ciaravino
Journal:  Arch Neurol       Date:  1992-11

9.  Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.

Authors:  G W Small; J C Mazziotta; M T Collins; L R Baxter; M E Phelps; M A Mandelkern; A Kaplan; A La Rue; C F Adamson; L Chang
Journal:  JAMA       Date:  1995 Mar 22-29       Impact factor: 56.272

10.  Neuropsychological detection and characterization of preclinical Alzheimer's disease.

Authors:  D M Jacobs; M Sano; G Dooneief; K Marder; K L Bell; Y Stern
Journal:  Neurology       Date:  1995-05       Impact factor: 9.910

View more
  13 in total

1.  A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer's disease.

Authors:  Montserrat Alegret; Gemma Cuberas-Borrós; Georgina Vinyes-Junqué; Ana Espinosa; Sergi Valero; Isabel Hernández; Isabel Roca; Agustín Ruíz; Maitée Rosende-Roca; Ana Mauleón; James T Becker; Joan Castell-Conesa; Lluís Tárraga; Mercè Boada
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Asymmetry in auditory and spatial attention span in normal elderly genetically at risk for Alzheimer's disease.

Authors:  Mark W Jacobson; Dean C Delis; Mark W Bondi; David P Salmon
Journal:  J Clin Exp Neuropsychol       Date:  2005-02       Impact factor: 2.475

Review 3.  Neuropsychological contributions to the early identification of Alzheimer's disease.

Authors:  Mark W Bondi; Amy J Jak; Lisa Delano-Wood; Mark W Jacobson; Dean C Delis; David P Salmon
Journal:  Neuropsychol Rev       Date:  2008-03-18       Impact factor: 7.444

4.  Quantitative MRI findings and cognitive impairment among community dwelling elderly subjects.

Authors:  H Koga; T Yuzuriha; H Yao; K Endo; S Hiejima; Y Takashima; F Sadanaga; T Matsumoto; A Uchino; K Ogomori; A Ichimiya; H Uchimura; N Tashiro
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

Review 5.  ApoE and cerebral insulin: Trafficking, receptors, and resistance.

Authors:  Elizabeth M Rhea; Jacob Raber; William A Banks
Journal:  Neurobiol Dis       Date:  2020-01-21       Impact factor: 5.996

6.  N-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI).

Authors:  Jerzy Walecki; Maria Barcikowska; Jarosław B Ćwikła; Tomasz Gabryelewicz
Journal:  Med Sci Monit       Date:  2011-12

7.  Age-related mild cognitive deficit: a ready-to-use concept?

Authors:  Christian Gilles
Journal:  Dialogues Clin Neurosci       Date:  2003-03       Impact factor: 5.986

8.  Improved motor and cognitive performance with sodium nitrite supplementation is related to small metabolite signatures: a pilot trial in middle-aged and older adults.

Authors:  Jamie N Justice; Lawrence C Johnson; Allison E DeVan; Charmion Cruickshank-Quinn; Nichole Reisdorph; Candace J Bassett; Trent D Evans; Forrest A Brooks; Nathan S Bryan; Michel B Chonchol; Tony Giordano; Matthew B McQueen; Douglas R Seals
Journal:  Aging (Albany NY)       Date:  2015-11       Impact factor: 5.682

9.  A review of SPECT studies in psychiatry in China.

Authors:  Shenxun Shi; Liang Shu
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

Review 10.  Mild cognitive impairment: conceptual issues and structural and functional brain correlates.

Authors:  Andrew J Saykin; Heather A Wishart
Journal:  Semin Clin Neuropsychiatry       Date:  2003-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.